What are the characteristics of BIOTALYS stock?

BIOTALYS is a company operating in the Produits Chimiques sector. The stock is listed on Euronext Brussels under ISIN BE0974386188.

What is the recent price evolution of BIOTALYS stock?

Since last close: -1.53 %. Over one week: -2.03 %. Over one year: -11.85 %.

Biotalys: CEO and Two Executives Depart the Company

Biotalys announces several changes within its governance bodies. The board of directors is reduced from eight to six members and the executive committee from four to two members.

Published on Mar 17, 2026 at 08:28

BIOTALYS

2.90 € -1.53 %

Immediate Departures in Leadership

Laura Meyer, a board member and chair of the audit committee since September 2024, leaves her position with immediate effect. Kevin Helash, CEO since October 2023, also departs the company with immediate effect. Kamal El Mernissi, director of business development since October 2024, will leave the company effective March 31, 2026.

Interim and New Appointments

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

Carlo Boutton, currently the chief scientific officer, will assume the role of interim CEO. Patrik Haesen has been appointed by the board to take over as chair of the audit committee.

Context

Period

Period: 2025

Guidance from the release

En 2025, nous avons atteint un point d'inflexion majeur avec l'approbation de notre premier biocontrole.
Nous renforçons notre concentration sur les programmes de biofongicides les plus avancés.

Risks mentioned

Biotalys n'a pas suffisamment de fonds de roulement pour couvrir ses besoins pendant au moins 12 mois.
La société a seulement une visibilité de trésorerie jusqu'à fin mai 2026.

Opportunities identified

Partenariat stratégique avec AgroFresh pour le marché post-récolte.
Développement de programmes avancés de biofongicides.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Immediate Departures in Leadership

Interim and New Appointments

Context

Also read